Velicept lines up for $21M; Scientists unveil improved gene editing tool;

@FierceBiotech: Real R&D innovation demands that lines between academia and industry are blurred. Article | Follow @FierceBiotech

@JohnCFierce: Disgraced scientist's China venture resurrects fears of a human cloning comeback. Story | Follow @JohnCFierce

@DamianFierce: Actually, inversions are ... good? More from the NYT | Follow @DamianFierce

> Velicept Therapeutics closed the first tranche of a $21 million B round, earmarking the funds for a Phase II study of solabegron, an in-development treatment for overactive bladder. More

> Researchers have developed a revamped CRISPR technology they say can edit genetic code with fewer errors than previous methods. Story

> New York's Remedy Pharmaceuticals raised $9 million to support its development of an intravenous treatment for stroke. News

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article | Follow @FierceMedDev

@VarunSaxena2: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: A behind-the-scenes look at Cards Against Biotechnology, Cubist's snarky 'last hurrah': FiercePharmaMarketing item | Follow @EmilyWFierce

> Nevro scores a victory in spinal cord stimulation patent battle with Boston Scientific. Article

> Q&A: Philips on what's next after the first year of HealthTech. Report

Pharma News

@FiercePharma: Japan reaping the benefits from faster approval process. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce:  last week: FDA warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce:  last week: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Russia amps up spending on locally made meds to spur Big Pharma production. Item

> Allergan investors still too 'skeptical' about a Pfizer merger, analyst says. Report

> Express Scripts backs Imprimis' $1-per-pill rival to Turing's pricey Daraprim. Article

Pharma Manufacturing News

> Xellia buys idled Bedford plant from Hikma, will hire 170. Report

> FDA warning letter blasts Dr. Reddy's for undisclosed testing. News

> Samsung BioLogics to build its third and largest plant in South Korea. Story

> Meda sells off Spain operation that makes Legalon API. Article

> GE investing $40M in Ireland plant and will add 140 jobs. Item

Pharma Asia News

> Pharmaceuticals in South Korea could drive economy's growth. Item

> Survey: Rates of HIV in Asia could reflect 'hidden epidemic.' More

> Israel's Teva and Takeda tie up for Japan generics business. Report

> Delhi court rules for Dr. Reddy's in Xarelto case. Story

> Russia hopes to lure drugmakers with increase in buying power. Article

Drug Delivery News

> Nature: Electronic on-demand delivery device is also bioresorbable. More

> Indian Institute of Science develops hep C delivery vehicle using siRNA. Story

> UCSD develops tech to isolate drug-delivery nanoparticles from the blood. Item

> Presage licenses cancer drug from India's Piramal to accelerate development using its microinjector. Report

> Impax earns permission to sell its FDA-approved modified-release Parkinson's med in Europe. Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.